cefixime has been researched along with cefadroxil anhydrous in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, SD; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Pfaller, MA; Washington, JA | 1 |
| Faulkner, RD; Hiltke, MF; McAteer, JA; Silber, BM | 1 |
| Verbist, L; Verhaegen, J | 1 |
| Clauss, W; Daniel, H; Gebert, I; Weber, WM; Weintraut, H; Wenzel, U | 1 |
| Inui, K; Mukai, M; Saito, H; Terada, T | 1 |
| Hayashi, K; Higashida, H; Miyamoto, K; Nakanishi, T; Sai, Y; Shiraga, T; Takeda, E; Tamai, I; Terao, T; Tsuji, A | 1 |
| Carter, AL; Ganapathy, ME; Ganapathy, V; Huang, W; Iseki, K; Leibach, FH; Rajan, DP; Sugawara, M | 1 |
| Brandsch, M; Luckner, P | 1 |
| Tsuji, A | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Aldini, G; De Luca, L; Marconi, C; Pedretti, A; Regazzoni, L; Vistoli, G | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cefixime and cefadroxil anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for cefixime and cefadroxil anhydrous
| Article | Year |
|---|---|
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
Topics: Anti-Bacterial Agents; Cefaclor; Cefadroxil; Cefdinir; Cefixime; Cefotaxime; Cefuroxime; Cephalosporins; Drug Evaluation, Preclinical; Enterobacteriaceae; Gram-Negative Aerobic Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests | 1992 |
Liquid-chromatographic determination of five orally active cephalosporins--cefixime, cefaclor, cefadroxil, cephalexin, and cephradine--in human serum.
Topics: Cefaclor; Cefadroxil; Cefixime; Cefotaxime; Cephalexin; Cephalosporins; Cephradine; Chromatography, High Pressure Liquid; Humans; Reference Standards; Reference Values | 1987 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
Topics: Animals; Biological Transport; Caco-2 Cells; Carrier Proteins; Cephalosporins; Humans; Hydrogen-Ion Concentration; Membrane Potentials; Oocytes; Peptide Transporter 1; Rabbits; Symporters; Xenopus laevis | 1996 |
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
Topics: Animals; Anti-Bacterial Agents; Biological Transport; Carrier Proteins; Ceftibuten; Cephalosporins; Cyclacillin; Dipeptides; Hydrogen-Ion Concentration; Kidney; Kinetics; LLC-PK1 Cells; Peptide Transporter 1; Rats; Recombinant Proteins; Structure-Activity Relationship; Symporters; Transfection | 1997 |
The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbon Radioisotopes; Carrier Proteins; Dipeptides; Female; Intestinal Absorption; Intestine, Small; Male; Peptide Transporter 1; Rats; Rats, Sprague-Dawley; Symporters; Xenopus laevis | 1997 |
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
Topics: Acetylcarnitine; Animals; Anti-Bacterial Agents; Carnitine; Carrier Proteins; Cefadroxil; Cefepime; Cephaloridine; Cephalosporins; Dose-Response Relationship, Drug; HeLa Cells; Humans; Kinetics; Membrane Proteins; Nitrogen; Organic Cation Transport Proteins; Rats; Sodium; Solute Carrier Family 22 Member 5; Tumor Cells, Cultured | 2000 |
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Transporter-mediated Drug Interactions.
Topics: | 2002 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
Topics: Binding Sites; Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Peptides; Protein Binding; Structural Homology, Protein; Symporters | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |